Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, non-randomized and single-center phase I/II clinical study,
to evaluate the the safety, tolerance and efficacy of Lenvatinib plus Camrelizumab as
first-line therapy in patients with advanced Hepatocellular Carcinoma.